A Study of the Long‑term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Sponsor ID
SEP361-304
Clinicaltrials.gov ID
NCT04115319
EudraCT ID
2019-002259-40
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Study Complete
Sponsor ID
SEP361-304
Trial Details
Subscribe for updates
Age
18 - 65 Years
Therapeutic Area
  • Schizophrenia
    • Sex
    Female & Male
    Trial Dates
    Nov 2019 - Dec 2022
    Healthy Volunteers
    No
    • The main inclusion criteria include, but are not limited to the following:
    • Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.
    • Participant meets DSM-5 criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the DSM-5 as a reference and confirmed using the SCID-CT). The time since the participant's diagnosis must be ≥ 1 year prior to Screening.
    • Participant must have a CGI-S score ≤ 4 at Screening and Baseline.
    • Participant must have a PANSS total score ≤ 80 at Screening and Baseline.
    • Participant is judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Screening.
    • Participant has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening.
    • Participants taking an antipsychotic agent at Screening may participate in this study only if there are signs of intolerability or lack of efficacy of the current antipsychotic (as determined by the Investigator).
    • Participant is, in the opinion of the Investigator, generally healthy based on Screening medical history, PE, neurological examination, vital signs, electrocardiogram (ECG) and clinical laboratory values (hematology, chemistry and urinalysis).
    • Main exclusion criteria include, but are not limited to:
    • Participant was hospitalized for a psychiatric illness within the 8 weeks prior to Screening.
    • Participant has a current DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, schizoaffective disorder, ,bipolar I or II disorder, obsessive compulsive disorder, and posttraumatic stress disorder, symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as theses symptoms are not the primary focus of treatment.
    • Participant is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents within a 1-year period prior to Screening, given at adequate dose as per labeling, for at least 4 weeks.
    • Participant answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Screening (i.e., in the past one month) or at Baseline (i.e., since last visit).
    • Participant is at significant risk of harming self or others based on Investigator's judgment.
    • Participant has attempted suicide within 6 months prior to Screening.
    • Participant has received treatment with a psychotropic medication or herbal supplement within 3 days or 5 half-lives (whichever is longer)
    • Participant has been treated with quetiapine or quetiapine XR within the 6 weeks prior to Screening or has a history of inadequate response or intolerability to quetiapine or quetiapine XR.
    • Participant has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in the study.
    • Participant has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.

    Study Summary

    A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia.

    This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.

    Additional Study Details

    Phase
    Phase 3
    Study Drug
    Drug: SEP363856
    Type
    Interventional
    Masking
    Quadruple
    Estimated Enrollment
    305
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • The main inclusion criteria include, but are not limited to the following:
    • * Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.

    Exclusion Criteria

    • Main exclusion criteria include, but are not limited to:
    • * Participant was hospitalized for a psychiatric illness within the 8 weeks prior to Screening.
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • The main inclusion criteria include, but are not limited to the following:
    • Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.
    • Participant meets DSM-5 criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the DSM-5 as a reference and confirmed using the SCID-CT). The time since the participant's diagnosis must be ≥ 1 year prior to Screening.
    • Participant must have a CGI-S score ≤ 4 at Screening and Baseline.
    • Participant must have a PANSS total score ≤ 80 at Screening and Baseline.
    • Participant is judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Screening.
    • Participant has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening.
    • Participants taking an antipsychotic agent at Screening may participate in this study only if there are signs of intolerability or lack of efficacy of the current antipsychotic (as determined by the Investigator).
    • Participant is, in the opinion of the Investigator, generally healthy based on Screening medical history, PE, neurological examination, vital signs, electrocardiogram (ECG) and clinical laboratory values (hematology, chemistry and urinalysis).
    Exclusion Criteria:
    • Main exclusion criteria include, but are not limited to:
    • Participant was hospitalized for a psychiatric illness within the 8 weeks prior to Screening.
    • Participant has a current DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, schizoaffective disorder, ,bipolar I or II disorder, obsessive compulsive disorder, and posttraumatic stress disorder, symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as theses symptoms are not the primary focus of treatment.
    • Participant is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents within a 1-year period prior to Screening, given at adequate dose as per labeling, for at least 4 weeks.
    • Participant answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Screening (i.e., in the past one month) or at Baseline (i.e., since last visit).
    • Participant is at significant risk of harming self or others based on Investigator's judgment.
    • Participant has attempted suicide within 6 months prior to Screening.
    • Participant has received treatment with a psychotropic medication or herbal supplement within 3 days or 5 half-lives (whichever is longer)
    • Participant has been treated with quetiapine or quetiapine XR within the 6 weeks prior to Screening or has a history of inadequate response or intolerability to quetiapine or quetiapine XR.
    • Participant has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in the study.
    • Participant has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.

    Study Documents

    Study Protocol
    Available Languages: English
    DOWNLOAD DOCUMENT(S)
    Statistical Analysis Plan
    Available Languages: English
    DOWNLOAD DOCUMENT(S)

    Locations

    Location
    Status
    Location
    Research Site
    Cerritos, California, United States, 90703
    Status
    N/A
    Location
    Research Site
    Oakland, California, United States, 94607
    Status
    N/A
    Location
    Research Site
    Oceanside, California, United States, 92056
    Status
    N/A
    Location
    Research Site
    San Diego, California, United States, 92103
    Status
    N/A
    Location
    Research Site
    Torrance, California, United States, 90502
    Status
    N/A
    Location
    Research Site
    Miami, Florida, United States, 33122
    Status
    N/A
    Showing {first} - {last} of {total} Results

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974